Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON59219Phase 2Active, not recruiting
Phase 2, randomised, double-blind trial of avapritinib in indolent systemic mastocytosis (ISM) (4 arms), sponsored by Blueprint Medicines. Primary endpoints: Recommended phase 2 dose, Change in ISM-SAF total symptom score and 1 more. Started Apr 2019; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON59219.